Shortage of Sufentanil Citrate Injection: FDA Status Update
Sufentanil Citrate Injection is currently listed in the FDA Drug Shortage Database, with one manufacturer reporting availability as of March 27, 2026.
What's in Shortage
The drug in shortage is Sufentanil Citrate Injection. Its generic name is Sufentanil Citrate Injection, and the brand name is SUFENTANIL CITRATE. The dosage form is Injection, and the current status is Current. It falls under the therapeutic categories of Analgesia/Addiction and Pediatric. The shortage was first posted on May 3, 2022, and last updated on March 27, 2026.
Which Manufacturers Are Affected
The affected manufacturer is Hospira, Inc., a Pfizer Company. Their availability status is Available for the presentation Sufentanil Citrate, Injection, 50 ug/1 mL (NDC 0409-3382-21). Contact information for this manufacturer is 844-646-4398.
Why There's a Shortage
No specific reason was provided for the shortage.
What Patients Should Do
Patients who depend on this medication should speak with their pharmacist or healthcare provider to check on availability and discuss options. They can contact the manufacturer for more details. Please remember that patients should consult their healthcare provider for any guidance and not make changes to their medication without professional advice.
Source
This information is from the FDA Drug Shortage Database.
Source: FDA Official Notice